TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
Post-LOEpolymyxin b sulfate and trimethoprim sulfate
ANDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 2024
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE (polymyxin b sulfate and trimethoprim sulfate) by Bausch + Lomb is dihydrofolate reductase inhibitors [moa]. First approved in 2024.
Drug data last refreshed 1w ago
Mechanism of Action
Dihydrofolate Reductase Inhibitors
Pharmacologic Class:
Dihydrofolate Reductase Inhibitor Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.